Copyright: ©Author(s) 2026.
World J Meta-Anal. Jun 18, 2026; 14(2): 121391
Published online Jun 18, 2026. doi: 10.13105/wjma.v14.i2.121391
Published online Jun 18, 2026. doi: 10.13105/wjma.v14.i2.121391
Table 1 Databases and search terms used during the study
| Database | Search date | Search terms |
| PubMed | September 17, 2025 | (Ivermectin[MeSH Terms] OR ivermectin OR avermectin) AND (Neoplasms[MeSH Terms] OR cancer OR carcinoma OR tumor OR neoplasm OR malignan OR oncology) AND (therapy OR treatment OR intervention OR effect OR outcome OR response OR inhibition OR cytotoxicity OR anti-cancer OR anticancer OR anti-tumor OR antitumor) |
| EMBASE | September 17, 2025 | Ivermectin/OR ivermectin.mp. OR (ivermect OR stromectol OR mectizan OR sklice).tw,kw. AND exp neoplasm/OR (cancer OR tumor OR tumour OR neoplas OR malignan OR carcinoma OR sarcoma OR lymphoma OR leukemia OR leukaemia OR oncology).tw,kw. AND exp cancer therapy/OR exp antineoplastic therapy/OR (therapOR treat OR adjunct OR adjuvant OR drug reposition OR drug repurpos) |
- Citation: Olunga R, Jaoko W, Kipkoech R, Natalia G, Tai RJ, Mutanu L, Jengo M, Mwangi FW, Ayuma O, Anosike UG. Molecular targets of ivermectin as a potential repurposed drug in cancer therapy: A scoping review. World J Meta-Anal 2026; 14(2): 121391
- URL: https://www.wjgnet.com/2308-3840/full/v14/i2/121391.htm
- DOI: https://dx.doi.org/10.13105/wjma.v14.i2.121391